PURPOSE: The purpose of this study was to develop and test a brief scale (Brief Evaluation of Medication Influences and Beliefs [BEMIB]) designed to identify patients who are more likely to be nonadherent to their antipsychotic medication. METHODS: Sixty-three outpatients with schizophrenia and related psychotic disorders were enrolled and given an assessment battery including the BEMIB, a previously published adherence scale, extrapyramidal symptom rating scales, and an adherence assessment with patient self-report and prescription refill records. The BEMIB consisted of 8 statements derived from the health belief model with a 5-point Likert-type scale for each statement. Subjects chose a single answer for each item depending on their level of agreement or disagreement. RESULTS: According to refill records, subjects meeting BEMIB-based criteria for nonadherence had significantly larger gaps in antipsychotic therapy (greater nonadherence) compared with those of participants not meeting criteria for nonadherence. For the 1-week test-retest reliability, the BEMIB total score and 5 of 8 single items correlated significantly. BEMIB total scores correlated significantly with an established assessment of adherence (Drug Attitude Inventory), demonstrating adequate construct validity. CONCLUSION: The BEMIB represents a promising scale for identifying patients more likely to be nonadherent to their medications. Copyright 2004 Lippincott Williams and Wilkins
PURPOSE: The purpose of this study was to develop and test a brief scale (Brief Evaluation of Medication Influences and Beliefs [BEMIB]) designed to identify patients who are more likely to be nonadherent to their antipsychotic medication. METHODS: Sixty-three outpatients with schizophrenia and related psychotic disorders were enrolled and given an assessment battery including the BEMIB, a previously published adherence scale, extrapyramidal symptom rating scales, and an adherence assessment with patient self-report and prescription refill records. The BEMIB consisted of 8 statements derived from the health belief model with a 5-point Likert-type scale for each statement. Subjects chose a single answer for each item depending on their level of agreement or disagreement. RESULTS: According to refill records, subjects meeting BEMIB-based criteria for nonadherence had significantly larger gaps in antipsychotic therapy (greater nonadherence) compared with those of participants not meeting criteria for nonadherence. For the 1-week test-retest reliability, the BEMIB total score and 5 of 8 single items correlated significantly. BEMIB total scores correlated significantly with an established assessment of adherence (Drug Attitude Inventory), demonstrating adequate construct validity. CONCLUSION: The BEMIB represents a promising scale for identifying patients more likely to be nonadherent to their medications. Copyright 2004 Lippincott Williams and Wilkins
Authors: David L Penn; Sarah R Uzenoff; Diana Perkins; Kim T Mueser; Robert Hamer; Evan Waldheter; Sylvia Saade; Liz Cook Journal: Schizophr Res Date: 2011-02 Impact factor: 4.939
Authors: Dong Roman Xu; Wenjie Gong; Steve Gloyd; Eric D Caine; Jane Simoni; James P Hughes; Shuiyuan Xiao; Wenjun He; Bofeng Dai; Meijuan Lin; Juan Nie; Hua He Journal: Schizophr Res Date: 2018-05-26 Impact factor: 4.939
Authors: Delbert G Robinson; Nina R Schooler; Robert A Rosenheck; Haiqun Lin; Kyaw J Sint; Patricia Marcy; John M Kane Journal: Psychiatr Serv Date: 2019-05-14 Impact factor: 3.084
Authors: Martha Sajatovic; Dawn I Velligan; Peter J Weiden; Marcia A Valenstein; Gbenga Ogedegbe Journal: J Psychosom Res Date: 2009-07-25 Impact factor: 3.006
Authors: Dawn I Velligan; Yui-Wing Francis Lam; David C Glahn; Jennifer A Barrett; Natalie J Maples; Larry Ereshefsky; Alexander L Miller Journal: Schizophr Bull Date: 2006-05-17 Impact factor: 9.306
Authors: Fernando Cañas; Koksal Alptekin; Jean Michel Azorin; Vincent Dubois; Robin Emsley; Antonio G García; Philip Gorwood; Peter M Haddad; Dieter Naber; José M Olivares; Georgios Papageorgiou; Miquel Roca Journal: Clin Drug Investig Date: 2013-02 Impact factor: 2.859
Authors: Evan J Waldheter; David L Penn; Diana O Perkins; Kim T Mueser; Leanne Whaley Owens; Elizabeth Cook Journal: Community Ment Health J Date: 2008-05-31